Lyndra

Lyndra Therapeutics is developing a disruptive oral drug delivery platform that aims to radically improve medication adherence and patient outcomes by converting daily pills into weekly or monthly doses. Founded in 2015 and based in Watertown, Massachusetts, the company's core technology is a gastric-retentive dosage form that slowly releases medication in the stomach over an extended period. With a lead program in schizophrenia and a pipeline targeting chronic diseases, Lyndra is positioned to address a significant unmet need in long-term pharmacotherapy. The company is privately held and has secured substantial funding from prominent healthcare investors.

Proprietary long-acting oral (LAO) platform featuring a gastric-retentive, star-shaped dosage form that slowly releases medication over one week or one month from a single pill.

Lyndra competes with manufacturers of standard oral therapies and long-acting injectables (LAIs) in its target indications. Its primary differentiation is the non-invasive, oral route of administration for long-acting effect. Other companies are exploring alternative long-acting oral technologies (e.g., intestinal patches, bio-adhesive systems), but Lyndra's gastric-retentive approach is among the most advanced clinically.